Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

integria healthcare australia pty ltd - calcium hydrogen phosphate dihydrate,dibasic potassium phosphate,magnesium aspartate tetrahydrate,magnesium phosphate pentahydrate,magnesium amino acid chelate,manganese amino acid chelate,pyridoxine hydrochloride -

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - posaconazole 18 mg/ml;   - concentrate for injection - 300mg/16.7ml - active: posaconazole 18 mg/ml   excipient: disodium edetate hydrochloric acid sodium hydroxide sulfobutyl betadex sodium water for injection - noxafil (posaconazole) concentrated injection is indicated for use in the treatment of the following invasive fungal infections in adults: - invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. - fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. noxafil is also indicated for the: - prophylaxis of invasive fungal infections among adults, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.